References

  1. Retsky M, Demicheli R, Hrushesky W: Premenopausal status accelerates relapse in node positive breast cancer: hypothesis links angiogenesis, screening controversy.

    Breast Cancer Res Treat 2001, 65:217-224. PubMed Abstract | Publisher Full Text OpenURL

  2. Baum M, Chaplain MAJ, Anderson ARA, Douek M, Vaidya JS: Does breast cancer exist in a state of chaos?

    Eur J Cancer 1999, 35:886-891. PubMed Abstract | Publisher Full Text OpenURL

  3. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma.

    Cell 1994, 79:315-328. PubMed Abstract | Publisher Full Text OpenURL

  4. Hofer SO, Molema G, Hermens RA, Wanebo HJ, Reichner JS, Hoekstra HJ: The effect of surgical wounding on tumour development.

    Eur J Surg Oncol 1999, 25:231-243. PubMed Abstract | Publisher Full Text OpenURL

  5. Retsky M, Demicheli R, Hrushesky W: Breast cancer screening: controversies and future directions.

    Curr Opin Obstet Gynecol 2003, 15:1-8. PubMed Abstract | Publisher Full Text OpenURL

  6. Demicheli R, Bonadonna G, Hrushesky WJM, Retsky MW, Valagussa P: Menopausal status dependence of the early mortality reduction due to diagnosing smaller breast cancers (T1 versus T2-T3): relevance to screening.

    J Clin Oncol 2004, 22:102-107. PubMed Abstract | Publisher Full Text OpenURL

  7. Baines C: Mammography screening: are women really giving informed consent?

    J Natl Cancer Inst 2003, 95:1508-1511. PubMed Abstract | Publisher Full Text OpenURL

  8. Naumov GN, MacDonald IC, Weinmeister PM, Kerkvliet N, Nadkarni KV, Wilson SM, Morris VL, Groom AC, Chambers AF: Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy.

    Cancer Res 2002, 62:2162-2168. PubMed Abstract | Publisher Full Text OpenURL

  9. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C: Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up.

    N Engl J Med 1995, 332:901-906. PubMed Abstract | Publisher Full Text OpenURL

  10. NIH consensus conference: Adjuvant chemotherapy for breast cancer.

    JAMA 1985, 254:3461-3463. PubMed Abstract OpenURL

  11. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: an overview of the randomised trials.

    Lancet 1998, 352:930-942. PubMed Abstract | Publisher Full Text OpenURL

  12. Miller AB, To T, Baines CJ, Wall C: The Canadian National Breast Screening Study-1: breast cancer mortality after 11 to 16 years of follow-up. A randomized screening trial of mammography in women age 40 to 49 years.

    Ann Intern Med 2002, 137:305-312. PubMed Abstract | Publisher Full Text OpenURL

  13. Demicheli R, Miceli R, Brambilla C, Ferrari L, Moliterni A, Zambetti M, Valagussa P, Bonadonna G: Comparative analysis of breast cancer recurrence risk for patients receiving or not receiving adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF). Data supporting the occurrence of 'cures'.

    Breast Cancer Res Treat 1999, 53:209-215. PubMed Abstract | Publisher Full Text OpenURL